Blockade of CD47 or SIRPα: a new cancer immunotherapy

References

• Murata Y, Kotani T, Ohnishi H, et al. The CD47-SIRPα signalling system: its physiological roles and therapeutic application. J Biochem. 2014 Jun;155(6):335–344.
   PubMed Web of Science ®Google Scholar
• Oldenborg PA, Zheleznyak A, Fang YF, et al. Role of CD47 as a marker of self on red blood cells. Science. 2000 Jun 16;288(5473):2051–2054.
   PubMed Web of Science ®Google Scholar
• Okazawa H, Motegi S, Ohyama N, et al. Negative regulation of phagocytosis in macrophages by the CD47-SHPS-1 system. J Immunol. 2005 Feb 15;174(4):2004–2011.
   PubMed Web of Science ®Google Scholar
• Oldenborg PA, Gresham HD, Lindberg FP. CD47-signal regulatory protein α (SIRPα) regulates Fcγ and complement receptor-mediated phagocytosis. J Exp Med. 2001 Apr 2;193(7):855–862.
   PubMed Web of Science ®Google Scholar
• Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009 Jul 23;138(2):286–299.
   PubMed Web of Science ®Google Scholar
• Chao MP, Alizadeh AA, Tang C, et al. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010 Sep 3;142(5):699–713.
   PubMed Web of Science ®Google Scholar
• Matlung HL, Szilagyi K, Barclay NA, et al. The CD47-SIRPα signaling axis as an innate immune checkpoint in cancer. Immunol Rev. 2017 Mar;276(1):145–164.
   PubMed Web of Science ®Google Scholar
• Weiskopf K. Cancer immunotherapy targeting the CD47/SIRPα axis. Eur J Cancer. 2017 May;76:100–109.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Ring AM, Ho CC, et al. Engineered SIRPα variants as immunotherapeutic adjuvants to anticancer antibodies. Science. 2013 Jul 5;341(6141):88–91.
   PubMed Web of Science ®Google Scholar
• Zhao XW, van Beek EM, Schornagel K, et al. CD47-signal regulatory protein-α (SIRPα) interactions form a barrier for antibody-mediated tumor cell destruction. Proc Natl Acad Sci U S A. 2011 Nov 8;108(45):18342–18347.
   PubMed Web of Science ®Google Scholar
• Yanagita T, Murata Y, Tanaka D, et al. Anti-SIRPα antibodies as a potential new tool for cancer immunotherapy. JCI Insight. 2017 Jan 12;2(1):e89140.
   PubMed Web of Science ®Google Scholar
• Voets E, Parade M, Lutje Hulsik D, et al. Functional characterization of the selective pan-allele anti-SIRPα antibody ADU-1805 that blocks the SIRPα-CD47 innate immune checkpoint. J Immunother Cancer. 2019 Dec 4;7(1):340.
   PubMed Web of Science ®Google Scholar
• Ring NG, Herndler-Brandstetter D, Weiskopf K, et al. Anti-SIRPα antibody immunotherapy enhances neutrophil and macrophage antitumor activity. Proc Natl Acad Sci U S A. 2017 Dec 5;114(49):E10578–E10585.
   PubMed Web of Science ®Google Scholar
• Sim J, Sockolosky JT, Sangalang E, et al. Discovery of high affinity, pan-allelic, and pan-mammalian reactive antibodies against the myeloid checkpoint receptor SIRPα. MAbs. 2019 Aug/Sep;11(6):1036–1052.
   PubMed Web of Science ®Google Scholar
• Kulkarni A, Chandrasekar V, Natarajan SK, et al. A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nat Biomed Eng. 2018 Aug;2(8):589–599.
   PubMed Web of Science ®Google Scholar
• Lian S, Xie R, Ye Y, et al. Simultaneous blocking of CD47 and PD-L1 increases innate and adaptive cancer immune responses and cytokine release. EBioMedicine. 2019 Apr;42:281–295.
   PubMed Web of Science ®Google Scholar
• Logtenberg MEW, Jansen JHM, Raaben M, et al. Glutaminyl cyclase is an enzymatic modifier of the CD47-SIRPα axis and a target for cancer immunotherapy. Nat Med. 2019 Apr;25(4):612–619.
   PubMed Web of Science ®Google Scholar
• Chao MP, Jaiswal S, Weissman-Tsukamoto R, et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med. 2010 Dec 22;2(63):63ra94.
   PubMed Web of Science ®Google Scholar
• Chen J, Zhong MC, Guo H, et al. SLAMF7 is critical for phagocytosis of haematopoietic tumour cells via Mac-1 integrin. Nature. 2017 Apr 27;544(7651):493–497.
   PubMed Web of Science ®Google Scholar
• Liu X, Pu Y, Cron K, et al. CD47 blockade triggers T cell-mediated destruction of immunogenic tumors. Nat Med. 2015 Oct;21(10):1209–1215.
   PubMed Web of Science ®Google Scholar
• Tseng D, Volkmer JP, Willingham SB, et al. Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response. Proc Natl Acad Sci U S A. 2013 Jul 2;110(27):11103–11108.
   PubMed Web of Science ®Google Scholar
• Sockolosky JT, Dougan M, Ingram JR, et al. Durable antitumor responses to CD47 blockade require adaptive immune stimulation. Proc Natl Acad Sci U S A. 2016 May 10;113(19):E2646–E2654.
   PubMed Web of Science ®Google Scholar
• Liu X, Liu L, Ren Z, et al. Dual targeting of innate and adaptive checkpoints on tumor cells limits immune evasion. Cell Rep. 2018 Aug 21;24(8):2101–2111.
   PubMed Web of Science ®Google Scholar
• Advani R, Flinn I, Popplewell L, et al. CD47 blockade by Hu5F9-G4 and rituximab in non-Hodgkin’s lymphoma. N Engl J Med. 2018 Nov 1;379(18):1711–1721.
   PubMed Web of Science ®Google Scholar
• Soto-Pantoja DR, Terabe M, Ghosh A, et al. CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy. Cancer Res. 2014 Dec 1;74(23):6771–6783.
   PubMed Web of Science ®Google Scholar
• Waclavicek M, Majdic O, Stulnig T, et al. T cell stimulation via CD47: agonistic and antagonistic effects of CD47 monoclonal antibody 1/1A4. J Immunol. 1997 Dec 1;159(11):5345–5354.
   PubMed Web of Science ®Google Scholar
• Seiffert M, Brossart P, Cant C, et al. Signal-regulatory protein α (SIRPα) but not SIRPβ is involved in T-cell activation, binds to CD47 with high affinity, and is expressed on immature CD34+CD38−hematopoietic cells. Blood. 2001 May 1;97(9):2741–2749.
   PubMed Web of Science ®Google Scholar
• Nath PR, Pal-Nath D, Mandal A, et al. Natural killer cell recruitment and activation are regulated by CD47 expression in the tumor microenvironment. Cancer Immunol Res. 2019 Sep;7(9):1547–1561.
   PubMed Web of Science ®Google Scholar
• Saito Y, Respatika D, Komori S, et al. SIRPα+ dendritic cells regulate homeostasis of fibroblastic reticular cells via TNF receptor ligands in the adult spleen. Proc Natl Acad Sci U S A. 2017 Nov 21;114(47):E10151–E10160.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Zhao F, et al. Pre-clinical development of a humanized anti-CD47 antibody with anti-cancer therapeutic potential. PLoS One. 2015 Sep 21;10(9):e0137345.
   PubMed Web of Science ®Google Scholar
• Sikic BI, Lakhani N, Patnaik A, et al. First-in-human, first-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers. J Clin Oncol. 2019 Apr 20;37(12):946–953.
   PubMed Web of Science ®Google Scholar
• Buatois V, Johnson Z, Salgado-Pires S, et al. Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B-cell lymphoma and leukemia. Mol Cancer Ther. 2018 Aug;17(8):1739–1751.
   PubMed Web of Science ®Google Scholar
• Dheilly E, Moine V, Broyer L, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017 Feb 1;25(2):523–533.
   PubMed Web of Science ®Google Scholar
• Piccione EC, Juarez S, Liu J, et al. A bispecific antibody targeting CD47 and CD20 selectively binds and eliminates dual antigen expressing lymphoma cells. MAbs. 2015;7(5):946–956.
   PubMed Web of Science ®Google Scholar
• Velliquette RW, Aeschlimann J, Kirkegaard J, et al. Monoclonal anti-CD47 interference in red cell and platelet testing. Transfusion. 2019 Feb;59(2):730–737.
   PubMed Web of Science ®Google Scholar
• Brierley CK, Staves J, Roberts C, et al. The effects of monoclonal anti-CD47 on RBCs, compatibility testing, and transfusion requirements in refractory acute myeloid leukemia. Transfusion. 2019 Jul;59(7):2248–2254.
   PubMed Web of Science ®Google Scholar
• Matozaki T, Murata Y, Okazawa H, et al. Functions and molecular mechanisms of the CD47-SIRPα signalling pathway. Trends Cell Biol. 2009 Feb;19(2):72–80.
   PubMed Web of Science ®Google Scholar
• Sato-Hashimoto M, Nozu T, Toriba R, et al. Microglial SIRPα regulates the emergence of CD11c+ microglia and demyelination damage in white matter. Elife. 2019 Mar;26:8.
   Google Scholar
• van Beek EM, Cochrane F, Barclay AN, et al. Signal regulatory proteins in the immune system. J Immunol. 2005 Dec 15;175(12):7781–7787.
   PubMed Web of Science ®Google Scholar
• Hayashi A, Ohnishi H, Okazawa H, et al. Positive regulation of phagocytosis by SIRPβ and its signaling mechanism in macrophages. J Biol Chem. 2004 Jul 9;279(28):29450–29460.
   PubMed Web of Science ®Google Scholar
• Lahoud MH, Proietto AI, Gartlan KH, et al. Signal regulatory protein molecules are differentially expressed by CD8− dendritic cells. J Immunol. 2006 Jul 1;177(1):372–382.
   PubMed Web of Science ®Google Scholar
• Piccio L, Vermi W, Boles KS, et al. Adhesion of human T cells to antigen-presenting cells through SIRPβ2-CD47 interaction costimulates T-cell proliferation. Blood. 2005 Mar 15;105(6):2421–2427.
   PubMed Web of Science ®Google Scholar
• Hazama D, Yin Y, Murata Y, et al. Macrocyclic peptide-mediated blockade of the CD47-SIRPα interaction as a potential cancer immunotherapy. Cell Chem Biol. 2020 Jul;1:S2451–9456(20)30231-2.
   Google Scholar